In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Hold rating on Emergent Biosolutions (EBS), with a price target of $60. The company’s shares closed yesterday at $45.38.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 2.7% and a 41.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Emergent Biosolutions is a Moderate Buy with an average price target of $66.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $73.89 and a one-year low of $39.64. Currently, Emergent Biosolutions has an average volume of 576.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats.
